Latest filingSep 10, 2026Most recent Form 4
KURA
Kura Oncology, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/11 to 09/11. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$235M2 buys
Total selling$44.9M2 sells
Net open-market+$190M4 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period5transactions
- P · Open-market buys · dominant2 · 40%
- S · Open-market sells2 · 40%
- A · Grants / awards1 · 20%
Activity by reported role
A joint filing can contribute to multiple roles5transactions
- PRES · dominant2 · 40%
- CCO1 · 20%
- Chief financial officer1 · 20%
- CLO1 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (3)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeWilson Troy EdwardCommon Stock · Indirect · by One Fish Two Fish Revocable Trust
479,194Aug 24, 2026
Bair Teresa BrophyCommon Stock · Direct
195,444Aug 19, 2026
Powl Brian T.Common Stock · Direct
169,269Aug 21, 2026
Fulk JenniferOption to purchase common stock · Direct
450,000Sep 08, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 11 → Sep 11
LessMore
Top insiders
By absolute net value across the selected period- WE+$2.4M
- BB-$397.7k
- PT-$51.7k
- FJ+$0
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
KURA transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| KURA | Fulk Jennifer | CFO | grant | 450k | $0 | A | — | 0.0% | 09/10 | 09/08 |
| KURA | WILSON TROY EDWARD | PRES | buy | 100k | $123M | P | +10.6% | 08/24 | 08/24 | |
| KURA | Powl Brian T. | CCO | sale10b5-1 | 4.34k | -$5.16M | S | +10.6% | 08/24 | 08/21 | |
| KURA | Bair Teresa Brophy | CLO | sale10b5-1 | 31.4k | -$39.7M | S | +6.5% | 08/21 | 08/19 | |
| KURA | WILSON TROY EDWARD | PRES | buy | 100k | $111M | P | +14.3% | 08/17 | 08/17 |
Kura Oncology, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Kura Oncology, Inc.?
Fulk Jennifer, Powl Brian T., WILSON TROY EDWARD, Bair Teresa Brophy.
When was the latest reported open-market purchase?
Wilson Troy Edward reported a buy on Aug 24, 2026 valued at $123M. Read the SEC filing.
When was the latest reported open-market sale?
Powl Brian T. reported a sale on Aug 21, 2026 valued at $5.16M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market buying in the selected period was $1,901,655.84. This describes filed transactions, not a bullish rating.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.